Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia V Kichina

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Cells|October 13, 2023
PAK1 and Therapy Resistance in MelanomaJulia V Kichina, Alexei Maslov, Eugene S Kandel
Oncogene|August 2, 2003
Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53Julia V Kichina, Sikha Rauth, Tapas K Das Gupta, et al.
Expert Opinion on Therapeutic Targets|May 29, 2010
PAK1 as a therapeutic targetJulia V Kichina, Anna Goc, Belal Al-Husein, et al.
International Journal of Molecular Sciences|November 13, 2021
Proteotoxic Stress as an Exploitable Vulnerability in Cells with Hyperactive AKTMahamat Babagana, Lorin R Brown, Hannah Z Slabodkin, et al.
Oncotarget|May 29, 2015
MicroRNA analysis suggests an additional level of feedback regulation in the NF-κB signaling cascadePeter Mechtler, Ruchi Singhal, Julia V Kichina, et al.
Molecular Carcinogenesis|October 2, 2019
The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapiesMahamat Babagana, Julia V Kichina, Hannah Slabodkin, et al.
International Journal of Molecular Sciences|December 30, 2025
Inhibitors of De Novo Guanylate Biosynthesis Enhance the Potency of MAPK Cascade Inhibitors Against Colorectal CancerAlexei A Maslov, Nicholas H Trageser, Julia V Kichina, et al.
Biomolecules|October 29, 2025
Inhibition of the RAC/PAK Signaling Axis Enhances the Potency of MAPK Cascade Inhibitors Against Uveal MelanomaAlexei A Maslov, Nicholas H Trageser, Julia V Kichina, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Cells|October 13, 2023
PAK1 and Therapy Resistance in MelanomaJulia V Kichina, Alexei Maslov, Eugene S Kandel
Oncogene|August 2, 2003
Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53Julia V Kichina, Sikha Rauth, Tapas K Das Gupta, et al.
Expert Opinion on Therapeutic Targets|May 29, 2010
PAK1 as a therapeutic targetJulia V Kichina, Anna Goc, Belal Al-Husein, et al.
International Journal of Molecular Sciences|November 13, 2021
Proteotoxic Stress as an Exploitable Vulnerability in Cells with Hyperactive AKTMahamat Babagana, Lorin R Brown, Hannah Z Slabodkin, et al.
Oncotarget|May 29, 2015
MicroRNA analysis suggests an additional level of feedback regulation in the NF-κB signaling cascadePeter Mechtler, Ruchi Singhal, Julia V Kichina, et al.
Molecular Carcinogenesis|October 2, 2019
The role of polo-like kinase 3 in the response of BRAF-mutant cells to targeted anticancer therapiesMahamat Babagana, Julia V Kichina, Hannah Slabodkin, et al.
International Journal of Molecular Sciences|December 30, 2025
Inhibitors of De Novo Guanylate Biosynthesis Enhance the Potency of MAPK Cascade Inhibitors Against Colorectal CancerAlexei A Maslov, Nicholas H Trageser, Julia V Kichina, et al.
Biomolecules|October 29, 2025
Inhibition of the RAC/PAK Signaling Axis Enhances the Potency of MAPK Cascade Inhibitors Against Uveal MelanomaAlexei A Maslov, Nicholas H Trageser, Julia V Kichina, et al.
Pageof 1